Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - April 2013

The National Institute of Health and Care Excellence (NICE) has published new guidance for the month of April 2013. This month there are four technology appraisals that impact upon primary care.

The Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (Xolair®) technology appraisal recommends this treatment as an option for treating severe persistent confirmed allergic IgE‑mediated asthma in individuals who need continuous or frequent treatment with oral corticosteroids. This recommendation is made provided the treatment is made available with the discount agreed in the patient access scheme.

The Gout - canakinumab (Ilaris®) technology appraisal was terminated because no evidence submission was received from the manufacturer. As such the treatment cannot be recommended.

The Idiopathic pulmonary fibrosis - pirfenidone (Esbriet®) technology appraisal is recommended for patients with a predicted FVC between 50% and 80% and provided the treatment is made available with the discount agreed in the patient access scheme. Treatment should be stopped if the predicted FVC decline by more than 10% in 12 months.

The Rheumatoid arthritis - abatacept (2nd line) (Orencia®) technology appraisal recommends this treatment in combination with methotrexate as an option for treating rheumatoid arthritis in adults whose disease has responded inadequately to two conventional DMARDs. This recommendation is based upon it being used in accordance with the recommendations for other biological DMARDs as defined in TA130 and provided the treatment is made available with the discount agreed in the patient access scheme.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - April 2013' on Email Share 'NICE Guidance - April 2013' on Delicious Share 'NICE Guidance - April 2013' on Digg Share 'NICE Guidance - April 2013' on Facebook Share 'NICE Guidance - April 2013' on Google+ Share 'NICE Guidance - April 2013' on reddit Share 'NICE Guidance - April 2013' on StumbleUpon Share 'NICE Guidance - April 2013' on Twitter

atomic-wealth

No Comments to “NICE Guidance - April 2013”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,028 spam comments.

atomic-wealth
fond-illness
summer